The accelerated timeline for eGFR data (Q3 2026) and potential sBLA submission (Q4 2026) is a significant positive catalyst for VERA. Traders should monitor for the eGFR readout in Q3 2026, as positive results would de-risk the path to full approval and could drive substantial upside.
Price Chart
Executive Summary
Vera Therapeutics announced alignment with the FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in IgA Nephropathy. eGFR results are now expected in Q3 2026, with a supplemental Biologics License Application for full approval planned in Q4 2026, pending results. This accelerates the potential path to full approval for the company's lead asset.
Key Facts
- Aligned with FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in IgA Nephropathy.
- eGFR results now expected in Q3 2026.
- Plans to submit supplemental Biologics License Application for full approval in Q4 2026, pending eGFR results.
- Filing date: June 2, 2026.
Financial Impact
No specific financial figures provided; the event accelerates a key regulatory catalyst for the company's only pipeline asset.
Risk Factors
- eGFR results may not support full approval, leading to significant downside.
- Regulatory timelines could slip, delaying the sBLA submission.
- Competing therapies in IgA Nephropathy could limit atacicept's commercial potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-252475 |
| Document: 0001193125-26-252475-index-headers.html | 0001193125-26-252475 |
| Document: 0001193125-26-252475-index.html | 0001193125-26-252475 |
| Document: 0001193125-26-252475.txt | 0001193125-26-252475 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $33.67 $34.00 | ▲ +0.98% | ▲ +0.16% | $30.13 (−10.53%) |
Aug 10, 2026 7w ago | 8-K | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | $30.13 (−0.54%) |
Aug 10, 2026 7w ago | Press Release | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | $30.13 (−0.54%) |
Jul 9, 2026 12w ago | 8-K | $42.45 $39.12 | ▼ −7.84% | ▼ −7.71% | $30.13 (−29.03%) |
Jul 7, 2026 12w ago | 8-K | $42.96 $43.13 | ▲ +0.40% | ▼ −0.16% | $30.13 (−29.88%) |
Jun 11, 2026 16w ago | Institutional Cluster | $33.65 $35.01 | ▲ +4.04% | ▲ +3.61% | $30.13 (−10.48%) |
Jun 2, 2026 17w ago | 8-K | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | $30.13 (−3.63%) |
Jun 2, 2026 17w ago | Press Release | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | $30.13 (−3.63%) |
May 7, 2026 21w ago | 8-K | $35.88 $39.15 | ▲ +9.11% | ▲ +7.61% | $30.13 (−16.04%) |
Feb 26, 2026 31w ago | 8-K | $42.35 $38.85 | ▼ −8.26% | ▼ −7.14% | $30.13 (−28.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access